Skip to main content

Hong, Junshik

Seoul National University · Medicine

About the Lab

Professor Hong Junshik's research lab specializes in hematological malignancies and thrombotic disorders, with a focus on myeloid neoplasms, venous thromboembolism (VTE), and the molecular mechanisms underlying treatment responses and disease progression. The lab investigates epigenetic therapies, particularly DNA-methyltransferase inhibitors, and their role in activating innate immune responses through endogenous retrovirus regulation. It also explores clinical patterns in hematopoietic stem cell transplantation, treatment-related infections, and long-term outcomes in Asian populations, leveraging national health insurance data for population-level insights. The lab integrates molecular biology with real-world clinical data to improve precision in diagnosis, treatment, and risk stratification in blood disorders.

myelodysplastic syndromesvenous thromboembolismepigenetic therapyhematopoietic stem cell transplantationmyeloproliferative neoplasms

Research Overview

Papers
296
Total Citations
2,980
Papers (5y)
138
Primary Field
Medicine

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
138total
2021
2022
2023
2024
2025
Citations per year (5y)
532total
20212022202320242025

Selected Papers

15
1
Article|93 citations·2011
Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma
Junshik Hong, Yukyung Lee, Yeonjeong Park, Seog Gyun Kim, Kyung Hoon Hwang, Soon Ho Park, Ji Hoon Jeong, Kyung‐Hee Kim, Jeong Yeal Ahn, Sanghui Park, Jinny Park, Jae Hoon Lee
SJR Q2FWCI 4.7Annals of Hematology
Pathology and Forensic MedicineMedicine
2
Article|78 citations·2018
Incidence of venous thromboembolism in Korea from 2009 to 2013
Junshik Hong, Ju Hyun Lee, Ho‐Young Yhim, Won-Il Choi, Soo‐Mee Bang, Heeyoung Lee, Doyeun Oh
SJR Q1FWCI 8.3PLoS ONEOA

The incidence of venous thromboembolism (VTE) is lower in Asian populations than in Western populations. The objective of the present study was to evaluate the annual age- and sex-adjusted incidence (ASR) of VTE from 2009 to 2013 in South Korea. In addition, annual change in the pattern of VTE treatment during the study period was estimated because a new direct oral anticoagulant (DOAC) had become available and was covered by health insurance in Korea beginning in January 2013. VTE cases from 20

Internal MedicineMedicine
3
Article|45 citations·2021
Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs
Yongsuk Ku, Joo‐Hwan Park, Ryeongeun Cho, Yong-Ki Lee, Hyoung-Min Park, Min A Kim, Kyunghoon Hur, Soo Young Byun, Jun Liu, Young-Suk Lee, David Shum, Dong‐Yeop Shin
SJR Q1FWCI 2.7Proceedings of the National Academy of SciencesOA

DNA-methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used clinically to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Decitabine activates the transcription of endogenous retroviruses (ERVs), which can induce immune response by acting as cellular double-stranded RNAs (dsRNAs). Yet, the posttranscriptional regulation of ERV dsRNAs remains uninvestigated. Here, we find that the viral mimicry and subsequent cell death in response to decitabine

Molecular BiologyBiochemistry, Genetics and Molecular Biology
4
Article|36 citations·2013
Comparison of Characteristics of Bacterial Bloodstream Infection between Adult Patients with Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
Junshik Hong, Song Mi Moon, Hee Kyung Ahn, Sun Jin Sym, Yoon Soo Park, Jinny Park, Yong Kyun Cho, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
FWCI 1.3Biology of Blood and Marrow TransplantationOA

Although autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are fundamentally different procedures, a tailored approach to bacterial bloodstream infection (BSI) according to the type of HSCT has not yet been suggested. We evaluated the characteristics of BSI after HSCT, with a focus on comparison of BSIs between recipients of autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT). Among 134 patients (59 received allo-HSCT and 75 received auto-HSCT) who underwent HSCT,

OncologyMedicine
5
Article|36 citations·2010
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
Junshik Hong, Sae‐Won Han, Hye Seon Ham, Tae‐Yong Kim, In Sil Choi, Byung-Su Kim, Do‐Youn Oh, Seock‐Ah Im, Gyeong Hoon Kang, Yung‐Jue Bang, Tae-You Kim
SJR Q1FWCI 1.2Cancer Chemotherapy and Pharmacology
OncologyMedicine
6
Article|33 citations·2019
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms
Junshik Hong, Ju Hyun Lee, Ja Min Byun, Ji Yun Lee, Youngil Koh, Dong‐Yeop Shin, Jeong‐Ok Lee, Sang Mee Hwang, Hyoung Soo Choi, Inho Kim, Sung‐Soo Yoon, Soo‐Mee Bang
SJR Q1FWCI 3.0Blood AdvancesOA

This study aimed to elucidate patterns of disease transformation to secondary myelofibrosis (SMF) or secondary acute myeloid leukemia (SAML) and the development of second primary malignancies in South Korean patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs). By using nationwide public health care insurance claims data, we identified and analyzed 7454 patients with MPNs who were newly diagnosed with essential thrombocythemia (ET), polycythemia vera (PV), or primary myelofibrosis

GeneticsMedicine
7
Article|32 citations·2007
Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung Cancer
Junshik Hong, Se Hoon Park, Soo Jin Na Choi, Seok Ho Lee, Kyu Chan Lee, Jae-Ik Lee, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Eunmi Nam
SJR Q2FWCI 1.6Japanese Journal of Clinical Oncology

Nail changes occur with more frequent and prolonged use of docetaxel.

DermatologyMedicine
8
Review|31 citations·2021
Updated recommendations for the treatment of venous thromboembolism
Junshik Hong, Seo‐Yeon Ahn, Yoo Jin Lee, Ji Hyun Lee, Jung Woo Han, Kyoung Ha Kim, Ho‐Young Yhim, Seung‐Hyun Nam, Hee‐Jin Kim, Jaewoo Song, Sung‐Hyun Kim, Soo‐Mee Bang
SJR Q2FWCI 4.3Blood ResearchOA

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is a condition characterized by abnormal blood clot formation in the pulmonary arteries and the deep venous vasculature. It is often serious and sometimes even fatal if not promptly and appropriately treated. Moreover, the later consequences of VTE may result in reduced quality of life. The treatment of VTE depends on various factors, including the type, cause, and patient comorbidities. Furthermore, bleedi

Internal MedicineMedicine
9
Article|30 citations·2015
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy
Seha Park, Junshik Hong, In-Cheol Hwang, Jeong Yeal Ahn, Eun Yeong Cho, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
SJR Q1FWCI 1.6Journal of Geriatric Oncology
Geriatrics and GerontologyMedicine
10
Article|29 citations·2014
Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐<scp>CHOP</scp> immunochemotherapy
Junshik Hong, Hyun Seon Woo, Hyunchul Kim, Hee Kyung Ahn, Sun Jin Sym, Jinny Park, Jeong Yeal Ahn, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
SJR Q1FWCI 1.2Cancer ScienceOA

The aim of the current study is to evaluate the prognostic value of anemia, an easily estimable parameter in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy. A total of 157 patients with newly diagnosed diffuse large B-cell lymphoma treated with ≥1 cycle of R-CHOP were included. Hemoglobin level without red cell transfusion within 7 days of initiation of treatment was chosen as a para

HematologyMedicine
11
Article|28 citations·2012
Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type.
Junshik Hong, Sanghui Park, Hae Lim Baek, Joo Hyun Jung, Il Gyu Kang, Sun Jin Sym, Jinny Park, Jeong Yeal Ahn, Eun Kyung Cho, Seon Tae Kim, Dong Bok Shin, Jae Hoon Lee
FWCI 1.6PubMedOA

Extranodal natural killer/T-cell lymphoma, nasal type (nasal ENKTL) is a distinct clinicopathologic entity of lymphoid tumors with variable size and differentiation of tumor cells. Nasal ENKTL is related to infection of the tumor cells with Epstein-Barr virus (EBV) and virtually all cases contain monoclonal episomal EBV DNA and detectable EBV encoded small nuclear RNAs (EBERs). Several clinical factors are known for their relation to the prognosis, but histopathologic prognostic factors of nasal

Pathology and Forensic MedicineMedicine
12
Review|28 citations·2016
Recent advances in multiple myeloma: a Korean perspective
Junshik Hong, Jae Hoon Lee
SJR Q2FWCI 1.6The Korean Journal of Internal MedicineOA

Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. Application of novel agents has resulted in significant improvement of treatment outcomes, and the advances are ongoing with the recent introduction and U.S. Food and Drug Administration's approval of ne

HematologyMedicine
13
Article|28 citations·2011
Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy
Junshik Hong, Sanghui Park, Jinny Park, Hyung Sun Kim, Kyung‐Hee Kim, Jeong Yeal Ahn, Min Young Rim, Minkyu Jung, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
SJR Q2FWCI 3.2Leukemia & lymphoma/Leukemia and lymphoma

The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were evaluated with respect to clinical characteristics, treatment efficacy, and survival. Immunohistochemistry of bcl-2, CD10, bcl-6, and MUM-1 was performed and pat

Pathology and Forensic MedicineMedicine
14
Article|26 citations·2019
Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies
Junshik Hong, Heekyung Park, Suhyun Park, Ahreum Lee, Yeon‐Hee Lee, Dong‐Yeop Shin, Youngil Koh, Ji‐Yeob Choi, Sung‐Soo Yoon, Youngnim Choi, Inho Kim
SJR Q2FWCI 1.9The Korean Journal of Internal MedicineOA

HSV-1 reactivation in the oral cavity was highly associated with CIOM in patients with HMs undergoing high-dose chemotherapy.

Pulmonary and Respiratory MedicineMedicine
15
Article|25 citations·2012
CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy
Junshik Hong, Sanghui Park, Jinny Park, Seung Jun Jang, Hee Kyung Ahn, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
SJR Q2FWCI 1.6Annals of Hematology
Pathology and Forensic MedicineMedicine

Research Areas

HematologyPathology and Forensic MedicinePulmonary and Respiratory MedicineGeneticsOncologyImmunology

Dive deeper into Hong, Junshik's research on Nubint

Open this lab's papers in the app to read with AI, summarize, and cite in your writing.